ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA grants EUA to Lilly’s bebtelovimab for Covid-19 treatment
February 15, 2022Bebtelovimab is indicated for treating mild-to-moderate Covid-19 in adults and paediatric patients aged 12 years and above. -
Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
February 14, 2022The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company (NYSE: LLY) announced today. -
Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options
February 11, 2022Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to supply up to 600,000 doses of investigational drug bebtelovimab for at least $720 million. -
FDA Approves New Antibody Drug to Fight Omicron Variant
February 11, 2022The U.S. Food and Drug Administration on Friday gave the nod for a new monoclonal antibody treatment that works against the omicron variant. -
FDA Grants Emergency Use Authorization for New Antibody Drug
February 11, 2022The U.S. Food and Drug Administration on Friday gave the nod for a new monoclonal antibody treatment that works against the Omicron variant.
Pharma Sources Insight January 2025
